Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Development of a marketable adjuvant candidate for vaccine applications

Project description

Synthetic adjuvants for vaccine development

Most vaccines contain adjuvants, ingredients that help strengthen the elicited immune responses. Many compounds have been employed as adjuvants, which either activate antigen-presenting cells or preserve the conformation of antigens to be presented. The ERC-funded ADJUVACCINE project has developed a platform for the synthesis of adjuvant lead compounds based on the naturally occurring saponins encountered in plants. Saponins exhibit emulsifying and foaming properties and have recently been approved as vaccine adjuvants. The ADJUVACCINE synthetic production of saponin adjuvants is scalable, reduces the cost of vaccine production, and can be incorporated into the production pipeline.

Objective

ADJUVACCINE seeks to leverage a breakthrough made in the ERC-2016-STG-716878 project to validate a synthetic technological platform for the scalable production of identified optimised saponin adjuvants for improved cost-effective vaccines. We have developed in the laboratory potent, safe, stable, and streamlined adjuvant leads that surpass the QS-21 natural product adjuvant, leading to patent applications and the interest of Pharma. In this PoC project, we aim to exploit our synthetic saponin technology to produce adjuvant/vaccine candidates at scale that outperform existing products more cost-effectively, lowering the risk profile of the commercialisation potential, while also achieving valorisation outcomes for market entry. The goal is to demonstrate the scalability of our innovative adjuvant technology and select an optimal adjuvant candidate in advanced preclinical settings for entering the vaccine market via spin-off formation following proper IPR strategy implementation and attraction of key investors/partners.
The breakthrough innovation potential of ADJUVACCINE lies in the exploitation of this adjuvant platform for large-scale production and selection of the best candidate lead for application in vaccines against various diseases, improving the available vaccine solutions. The high purity and excellent chemical control of our synthetic technology versus the heterogeneous natural product adjuvants, as well as its streamlined, scalable nature and low-cost profile are unique attributes of our platform that will be valorised herein, making it a potentially superior alternative to existing vaccine models with less structural definition and costlier timelines. The main objectives are 1) demonstrate our synthetic technology platform for the gram-scale production and selection of a candidate adjuvant lead; and 2) implement valorisation opportunities and verify the potential of spin-off creation by establishing an optimal IPR and public/private funding roadmap plan.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) ERC-2022-POC2

See all projects funded under this call

Host institution

ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 150 000,00
Address
PARQUE TECNOLOGICO EDIFICIO 801 A
48160 DERIO VIZCAYA
Spain

See on map

Region
Noreste País Vasco Gipuzkoa
Activity type
Research Organisations
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Beneficiaries (1)

My booklet 0 0